MedTrace Logo

A Placebo-controlled Trial of Percutaneous Coronary Intervention for the Relief of Stable Angina

NCT03742050 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 439

Last updated 2023-09-29

No results posted yet for this study

Summary

ORBITA-2 is a double blinded randomised placebo-controlled trial comparing the effects of coronary angioplasty versus placebo procedure on symptoms of stable angina without background anti-anginal therapy. Follow-up will be at 12 weeks.

Conditions

  • Stable Angina

Interventions

PROCEDURE

Percutaneous coronary intervention

Percutaneous coronary intervention with drug-eluting stents aiming to achieve complete revascularisation

Sponsors & Collaborators

  • Basildon and Thurrock Hospitals NHS FoundationTrust

    collaborator UNKNOWN

  • Imperial College London

    lead OTHER

Principal Investigators

  • Darrel Francis, MRCP · Imperial College London

  • Christopher A Rajkumar · Imperial College London

  • Rasha Al-Lamee · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-12
Primary Completion
2023-09-06
Completion
2023-09-06

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03742050 on ClinicalTrials.gov